Literature DB >> 26670894

Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient.

Christopher Haas1, Mary Rodriguez Ziccardi2, Jody Borgman3.   

Abstract

Abacavir hypersensitivity is a rare, yet significant adverse reaction that results in a spectrum of physical and laboratory abnormalities, and has been postulated to stem from a variety of aetiological factors. The major histocompatibility complex haplotype human leucocyte antigen (HLA)-B5701 is a significant risk factor in development of hypersensitivity reactions, yet only 55% of HLA-B5701+ individuals develop such reactions, suggesting a multifactorial aetiology. Nevertheless, prospective screening and avoidance of abacavir in these patients has limited adverse events. Within this spectrum of adverse events, abacavir-induced liver toxicity is exceedingly rare and reported events have ranged from mild elevations of aminotransferases to fulminant hepatic failure. We report the case of a 50-year-old Caucasian woman with a history significant for HIV, hepatitis C virus and a HLA-B5701+ status, transferred to our emergency department in a hypotensive state and found to have acute liver failure, acute renal failure and significant rhabdomyolysis following a change of highly active antiretroviral therapy regimen. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26670894      PMCID: PMC4680310          DOI: 10.1136/bcr-2015-212566

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  24 in total

1.  Abacavir rechallenge has to be avoided in case of hypersensitivity reaction.

Authors:  L Escaut; J Y Liotier; E Albengres; N Cheminot; D Vittecoq
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

3.  Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.

Authors:  A Rauch; D Nolan; A Martin; E McKinnon; C Almeida; Simon Mallal
Journal:  Clin Infect Dis       Date:  2006-05-26       Impact factor: 9.079

4.  Abacavir hypersensitivity reaction.

Authors:  Ross G Hewitt
Journal:  Clin Infect Dis       Date:  2002-03-19       Impact factor: 9.079

5.  Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function.

Authors:  H Izzedine; V Launay-Vacher; G Aymard; M Legrand; G Deray
Journal:  Nephron       Date:  2001-09       Impact factor: 2.847

6.  Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults.

Authors:  J A McDowell; G E Chittick; C P Stevens; K D Edwards; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors:  Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

8.  Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.

Authors:  M S Saag; A Sonnerborg; R A Torres; D Lancaster; B G Gazzard; R T Schooley; C Romero; D Kelleher; W Spreen; S LaFon
Journal:  AIDS       Date:  1998-11-12       Impact factor: 4.177

9.  Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses.

Authors:  M R Klein; S H van der Burg; E Hovenkamp; A M Holwerda; J W Drijfhout; C J Melief; F Miedema
Journal:  J Gen Virol       Date:  1998-09       Impact factor: 3.891

10.  Abacavir-reactive memory T cells are present in drug naïve individuals.

Authors:  Andrew Lucas; Michaela Lucas; Anette Strhyn; Niamh M Keane; Elizabeth McKinnon; Rebecca Pavlos; Ellen M Moran; Viola Meyer-Pannwitt; Silvana Gaudieri; Lloyd D'Orsogna; Spyros Kalams; David A Ostrov; Søren Buus; Bjoern Peters; Simon Mallal; Elizabeth Phillips
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

View more
  2 in total

1.  Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient.

Authors:  Muhammad Saad; Fernando Casado-Castillo; Paul Kelly
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

2.  Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients.

Authors:  David Brandariz; Alex Smithson; Vanesa Anton-Vazquez
Journal:  Indian J Sex Transm Dis AIDS       Date:  2017 Jul-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.